Information Provided By: 
Fly News Breaks for May 17, 2017
MDXG
May 17, 2017 | 06:28 EDT
Piper Jaffray analyst Matt O'Brien raised his price target for MiMedx Group shares to $18 after hosting investor meetings with management. Momentum in the company's core wound closure business continues and the franchise should generate "strong" revenue growth in the coming years, O'Brien tells investors in a research note. Further, the analyst expects pain management to a "meaningful value creator" for MiMedx over time. He keeps an Overweight rating on the shares.
News For MDXG From the Last 2 Days
There are no results for your query MDXG
